TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31868719

Group type: EXPERIMENTAL
Intervention: International Diabetes Federation (IDF) diagnostic criteria
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: WHO diagnostic criteria
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: AHA diagnostic criteria
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: ATP diagnostic criteria
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: NCEP ATPIII diagnostic criteria
Number of subjects: 163

Group type: COMPARATOR
Intervention: Regular exercise
Number of subjects: 163

Group type: COMPARATOR
Intervention: Working hours
Number of subjects: 163
Study: 31427877

Group type: COMPARATOR
Intervention: 2×day stretch training
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1×day stretch training
Number of subjects: 0
Study: 28644348

Group type: EXPERIMENTAL
Intervention: Lactulose mannitol ratio (L:M) test
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Acute phase proteins (C-reactive protein >5 mg/L or α-1 acid glycoprotein >100 mg/dL)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Myeloperoxidase and α-1 antitrypsin correlation
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: 1-factor partial least squares model with L:M as dependent variable
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Adjusted models for L:M
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Systemic inflammation
Number of subjects: 539
Study: 26564807

Group type: EXPERIMENTAL
Intervention: Medical Taping Concept (MTC) covering T-11 and T-12 dermatomes
Number of subjects: 129

Group type: COMPARATOR
Intervention: Another taping in both greater trochanter areas
Number of subjects: 129
Study: 23657486

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Diclofenac sodium (50 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 44
Study: 21442636

Group type: EXPERIMENTAL
Intervention: Pomalidomide therapy
Number of subjects: 32
Study: 19789514

Group type: EXPERIMENTAL
Intervention: Intravenous 0.5 mg/kg ketamine and peritonsillar 0.25% bupivacaine (3-5 ml per tonsil)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous saline and peritonsillar bupivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous and peritonsillar saline solution (placebo)
Number of subjects: 90
Study: 16794136

Group type: EXPERIMENTAL
Intervention: IV bolus injection of 2 mL/kg of nonionic iodine contrast material (300 mg I/mL) at 4 mL/s
Number of subjects: 171
Study: 12560759

Group type: EXPERIMENTAL
Intervention: Low fat (3.06 g/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Medium fat (16.56 g/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High fat (30.06 g/day)
Number of subjects: 28
Study: 10678628

Group type: EXPERIMENTAL
Intervention: NIPPV (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medical therapy only (Group B)
Number of subjects: 30
Study: 9496210

Group type: EXPERIMENTAL
Intervention: Reflective wrap
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-reflective wrap
Number of subjects: 20
Study: 8407387

Group type: EXPERIMENTAL
Intervention: Thoracic lymphatic pump
Number of subjects: 42

Group type: COMPARATOR
Intervention: Incentive spirometry
Number of subjects: 42
Study: 3954249

Group type: EXPERIMENTAL
Intervention: Ventilatory muscle endurance training (VMET)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intermittent positive pressure breathing (IPPB)
Number of subjects: 32
Study: 30636490

Group type: EXPERIMENTAL
Intervention: Intermittent infusion of N-Acetylcysteine (IV: 25 mg/kg bolus and then 25 mg/kg/8 hours 3 times)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous infusion of N-Acetylcysteine (IV: 25 mg/kg bolus and then 75 mg/kg over 24 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30772477

Group type: EXPERIMENTAL
Intervention: 40 IU/kg C1‐INH(SC) twice per week
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 60 IU/kg C1‐INH(SC) twice per week
Number of subjects: 126

Group type: COMPARATOR
Intervention: C1‐INH(SC) (both doses)
Number of subjects: 126
Study: 28578679

Group type: EXPERIMENTAL
Intervention: 16 hours of additional trunk exercises for 1 hour a day, 4 days a week for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive exercises for 1 hour a day, 4 days a week for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 16 hours of additional trunk exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive exercises
Number of subjects: 60
Study: 26138259

Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg daily for 13 weeks)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 154
Study: 24174172

Group type: EXPERIMENTAL
Intervention: AGSAV301
Number of subjects: 29

Group type: COMPARATOR
Intervention: Exforge
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: AGSAV301 and Exforge
Number of subjects: 29
Study: 20946414

Group type: EXPERIMENTAL
Intervention: 222G/N variants in patients admitted to the intensive-care unit (ICU)
Number of subjects: 131

Group type: COMPARATOR
Intervention: 222G/N variants in hospitalized patients in other units
Number of subjects: 131

Group type: COMPARATOR
Intervention: 222G/N variants in community patients
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Virus load in the lower respiratory tract
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Duration of illness in severe infection patients
Number of subjects: 131
Study: 19296244

Group type: EXPERIMENTAL
Intervention: FOLFOX7 neoadjuvant chemotherapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Laparoscopic treatment (control group)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FOLFOX7 neoadjuvant chemotherapy followed by laparoscopic treatment
Number of subjects: 15
Study: 17437804

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 4579

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4579
Study: 15156070

Group type: EXPERIMENTAL
Intervention: Carbatrol (CBR) at dosages of 800, 1200, 1600 mg/day
Number of subjects: 47

Group type: COMPARATOR
Intervention: Valproic acid (VPA)
Number of subjects: 47
Study: 11733868

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 9571389

Group type: EXPERIMENTAL
Intervention: Intensive behavioral approach with structured contingency management intervention (experimental condition)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard treatment (control condition)
Number of subjects: 40
Study: 7810041

Group type: EXPERIMENTAL
Intervention: Automated static perimetry
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Kinetic perimetry
Number of subjects: 232
Study: 3290356

Group type: EXPERIMENTAL
Intervention: Ketanserin treatment for 5 weeks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ketanserin treatment
Number of subjects: 13
Study: 30602192

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided caudal block (Group H)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Conventional caudal block (Group C)
Number of subjects: 266
Study: 27539402

Group type: EXPERIMENTAL
Intervention: Functional weight-bearing mobilization
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-weight-bearing cast immobilization
Number of subjects: 56
Study: 25761552

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles (CNs)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 24177681

Group type: EXPERIMENTAL
Intervention: Low intensity exercise
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Moderate to high intensity aerobic and resistance exercises
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (routine physiotherapy)
Number of subjects: 19
Study: 20960149

Group type: EXPERIMENTAL
Intervention: 2 days of indwelling catheterization
Number of subjects: 246

Group type: COMPARATOR
Intervention: 5 days of indwelling catheterization
Number of subjects: 246
Study: 19294642

Group type: EXPERIMENTAL
Intervention: 2dTCA (two-dimensional temporal clustering algorithm)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Event-related activation using known timing
Number of subjects: 12
Study: 17687099

Group type: EXPERIMENTAL
Intervention: Preventive treatment strategies including mucolytic agents, physiotherapy, exercise, antibiotics, nutritional strategies, anti-inflammatory treatments, and vaccinations against common respiratory pathogens.
Number of subjects: 0
Study: 15478388

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 8
Study: 15280530

Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist 1.0 mmol/ml)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Iohexol (Omnipaque 350)
Number of subjects: 21
Study: 10572674

Group type: EXPERIMENTAL
Intervention: Screening group (serum AFP test and ultrasound every 6 months)
Number of subjects: 18816

Group type: EXPERIMENTAL
Intervention: Follow-up screening every 6 months in screening group
Number of subjects: 18816

Group type: EXPERIMENTAL
Intervention: Screening group (not followed up every 6 months)
Number of subjects: 18816

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 18816
Study: 7547088

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg at night
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2166699

Group type: EXPERIMENTAL
Intervention: Pork Insulin (PI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Human Insulin (HI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pork Insulin (PI) after 20 min of hypoglycemia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Human Insulin (HI) after 20 min of hypoglycemia
Number of subjects: 30
Study: 7417630

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chlorpromazine reinstatement
Number of subjects: 18
Study: 31234651

Group type: EXPERIMENTAL
Intervention: Alternative medicine strategies for diabetes control
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Home remedies, commercial weight-loss products, and herbal teas
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Disclosure of alternative methods to providers
Number of subjects: 85
Study: 26505288

Group type: EXPERIMENTAL
Intervention: Pre-exposure to tempting unhealthy food (e.g. candy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25022780

Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Distracter task
Number of subjects: 72
Study: 21423053

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 96

Group type: COMPARATOR
Intervention: Vertebroplasty
Number of subjects: 96
Study: 20709866

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg, 4 times/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 24
Study: 17396059

Group type: COMPARATOR
Intervention: No Smoking (NS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Electrically Heated Cigarette Smoking System (EHCSS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Conventional Cigarettes (CC)
Number of subjects: 18
Study: 15878496

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination (SFC) product (50/250 microg bid via the Diskus inhaler)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11888872

Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy (RT)
Number of subjects: 435

Group type: COMPARATOR
Intervention: No axillary treatment
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Both groups (axillary RT and no axillary treatment)
Number of subjects: 435
Study: 10465075

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 film
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo film
Number of subjects: 20
Study: 7599449

Group type: EXPERIMENTAL
Intervention: Ultrasonic transmission velocity (UTV)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Stiffness (STF)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Broad-band ultrasonic attenuation (BUA)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Femoral neck BMD
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Spinal BMD
Number of subjects: 336
Study: 29025380

Group type: EXPERIMENTAL
Intervention: Early tracheostomy (<= 3 days after transplant)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Late tracheostomy (> 3 days after transplant)
Number of subjects: 39
Study: 28594783

Group type: EXPERIMENTAL
Intervention: 17α‐hydroxyprogesterone caproate (341 mg per week)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg per day)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 235
Study: 26237636

Group type: EXPERIMENTAL
Intervention: SonicFill system/bulk fill (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Herculite Ultra composite resin/incremental technique (Group C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: SonicFill system/bulk fill (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Herculite Ultra/incremental technique (Group D)
Number of subjects: 80
Study: 23795769

Group type: EXPERIMENTAL
Intervention: Exercise (15 min of moderate intensity stationary cycling)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (15 min completing ratings of neutral IAPS images)
Number of subjects: 144
Study: 21168857

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Kobayashi score
Number of subjects: 99
Study: 18514522

Group type: EXPERIMENTAL
Intervention: Fatigue trials
Number of subjects: 16

Group type: COMPARATOR
Intervention: No fatigue trials
Number of subjects: 16
Study: 16848203

Group type: EXPERIMENTAL
Intervention: Single application of triamcinolone acetonide
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dexamethasone‐neomycin drops
Number of subjects: 80
Study: 12765424

Group type: EXPERIMENTAL
Intervention: mepolizumab (SB 240563) anti‐IL‐5 antibody administered three times
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 10648040

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 9752908

Group type: EXPERIMENTAL
Intervention: Single injection transthecal technique using 3 cc of lignocaine and bupivacaine mixture
Number of subjects: 142

Group type: COMPARATOR
Intervention: Single injection subcutaneous technique using 3 cc of lignocaine and bupivacaine mixture
Number of subjects: 142
Study: 8210390

Group type: EXPERIMENTAL
Intervention: Long-term low-dose erythromycin therapy (200 mg three times daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 19
Study: 3333017

Group type: EXPERIMENTAL
Intervention: 880 mg calcium daily for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5 mg stanozolol daily for 12 weeks
Number of subjects: 20
Study: 31230484

Group type: EXPERIMENTAL
Intervention: Iron-Folic Acid (IFA) supplementation
Number of subjects: 647

Group type: COMPARATOR
Intervention: Experiencing heartburn and vomiting
Number of subjects: 647

Group type: COMPARATOR
Intervention: Unintended pregnancy and better education
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Acceptability of IFA supplement, number of antenatal care (ANC) visits, and being ever married
Number of subjects: 647
Study: 29242350

Group type: EXPERIMENTAL
Intervention: NT‐proBNP‐guided therapy
Number of subjects: 405

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 405
Study: 28351407

Group type: EXPERIMENTAL
Intervention: Maternal Fat Free Mass (FFM)
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Maternal Fat Free Mass (FFM) ≥ 40.76 kg (Upper quartile of participants)
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Increased maternal age
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Increased pre-pregnancy BMI
Number of subjects: 1150
Study: 26160302

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75 % without epinephrine (ROPI)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75 % with epinephrine 5 μg/mL (ROPI‐EPI)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison between ROPI and ROPI‐EPI
Number of subjects: 38
Study: 23200554

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30-45mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 22282728

Group type: EXPERIMENTAL
Intervention: 6.3 mm-long implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: 9.3 mm or longer implants
Number of subjects: 60
Study: 18443191

Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg/day)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Non-ACE inhibitor therapy
Number of subjects: 816
Study: 17343258

Group type: EXPERIMENTAL
Intervention: Infrared radiation of a tiled stove (3 hours, three times a week for 3 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control period (2 weeks without treatment)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Infrared radiation of a tiled stove
Number of subjects: 45
Study: 14665584

Group type: EXPERIMENTAL
Intervention: Sodium citrate ingestion (1 litre of solution containing 0.5 g of sodium citrate/kg body mass two hours before the run)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sodium citrate ingestion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (flavoured mineral water)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11789260

Group type: EXPERIMENTAL
Intervention: Astragalus‐Polygonum Anti‐Fibrosis Decoction (APAFD) for 48 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Jinshuibao capsule (JSBC) for 48 weeks
Number of subjects: 92
Study: 8977503

Group type: EXPERIMENTAL
Intervention: Topical levocabastine (0.05%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nedocromil (2%)
Number of subjects: 24
Study: 1335460

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6202971

Group type: EXPERIMENTAL
Intervention: Propranolol (0.19 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol (0.19 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Practolol (0.64 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no beta-blocker)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol treatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Practolol treatment
Number of subjects: 6
Study: 29313286

Group type: EXPERIMENTAL
Intervention: Once-daily single inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) 100 µg/62.5 µg/25 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-daily inhaled corticosteroid/long-acting β2-agonist therapy (budesonide/formoterol) 400 µg/12 µg
Number of subjects: 0
Study: 27744268

Group type: EXPERIMENTAL
Intervention: Standardized assessments of mental and motor development at ages 6, 12, and 24 months; intelligence, adaptive functioning, and motor skills at 10.7 years
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Standardized assessments at 10.7 years
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Demographics, comorbidity, and developmental outcomes
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Early life characteristics
Number of subjects: 123
Study: 25665513

Group type: EXPERIMENTAL
Intervention: Pure Exposure (n=14)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Guided Exposure (n=15)
Number of subjects: 29
Study: 23089047

Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride (BZK) gel
Number of subjects: 240

Group type: COMPARATOR
Intervention: Nonoxynol-9 (N-9) gel
Number of subjects: 240
Study: 21906507

Group type: EXPERIMENTAL
Intervention: Neighborhood context, home and family management practices, deviant peer affiliations, beliefs favorable to use
Number of subjects: 4027

Group type: EXPERIMENTAL
Intervention: Preventive efforts focusing on neighborhood deprivation, exposure to alcohol advertisements, and home risks and protective factors
Number of subjects: 4027
Study: 18713505

Group type: EXPERIMENTAL
Intervention: End-of-treatment chest radiograph (EOT CXR) showing persistent cavity
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: End-of-treatment chest radiograph (EOT CXR) showing resolved cavity
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: No cavity on baseline or 2-month CXR
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Persistent cavity on EOT CXR
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Resolved cavity by EOT CXR
Number of subjects: 1004
Study: 16540829

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (HI)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (MI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 21
Study: 15007396

Group type: COMPARATOR
Intervention: Standard protein diet (SP; 15% protein, 55% carbohydrate)
Number of subjects: 58

Group type: COMPARATOR
Intervention: High-protein diet (HP; 30% protein, 40% carbohydrate)
Number of subjects: 58
Study: 11345282

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 400 microg twice daily
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 200 microg twice daily
Number of subjects: 733

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) Diskhaler 250 microg twice daily
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 100 microg twice daily
Number of subjects: 733

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) Diskhaler
Number of subjects: 733
Study: 9236420

Group type: EXPERIMENTAL
Intervention: Xemilofiban 35 mg orally before and 20 to 25 mg TID for 30 days after angioplasty
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Xemilofiban
Number of subjects: 30